AGENUS INC
AGENNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $2.71 β $10.31
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 45.0M
- Next Earnings
- 2027-03-15
Fundamentals Snapshot
- Annual Revenue
- $114M
- Last Q Revenue
- $31M
- P/E Ratio
- 2.9
- P/S Ratio
- 2.0x
- EPS (TTM)
- $2.65
- Dividend Yield
- β
- Dilution (1yr)
- +38.5%
AGENUS INC
AGENAbout AGENUS INC
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFΓ TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Agenus Inc. (AGEN) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial Transcript
Agenus Inc. ( AGEN ) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial November 5, 2026 11:30 AM EST Company Participants Zack Armen - Vice President of Investor Relations & Corporate Development Robin Taylo

Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down
AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 tria

Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones
Agenus NASDAQ: AGEN expects to begin enrolling patients in the next few months for a Phase 3 trial of its investigational immunotherapy combination BOT/BAL in early-stage colon cancer, executives said during an investor

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the third quarter ended September 30, 2026, and highlighted p

Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #IO--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporat